Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Clinical Trial

Randomized Controlled Trial

Multicenter Study

Comparative Study

Research Support, U.S. Gov't, P.H.S.

Research Support, N.I.H., Extramural

Clinical Trial, Phase II

Review

Case Reports

Controlled Clinical Trial

Publication Year

From

Quick links

Individual year

2015

2008

2007

2006

2005

2004

2003

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Didanosine""[mesh_terms]

14 Results

Searching titles within these results

Unusual muscle disease in HIV infected patients.

S Roedling, D Pearl, H Manji, M G Hanna, J L Holton, R F Miller

Sexually transmitted infections 2004;80(4):315-7

Free Full Text

Abstract

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

Judith C Shlay, Fehmida Visnegarwala, Glenn Bartsch, Jack Wang, Grace Peng, Wafaa M El-Sadr, Cynthia Gibert, Donald Kotler, Carl Grunfeld, Subhasree Raghavan

Journal of acquired immune deficiency syndromes (1999) 2005;38(2):147-55

Full Text

Abstract

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

Ian Sanne, Peter Piliero, Kathleen Squires, Alexandra Thiry, Steven Schnittman

Journal of acquired immune deficiency syndromes (1999) 2003;32(1):18-29

Full Text

Abstract

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Esteban Ribera, Dolors Rodríguez-Pardo, Manuel Rubio, Anna Soler, Enric Pedrol, José L Blanco, Alicia González, Manel Crespo, Vicenç Falcó, Imma Ocaña, Elisabeth Deig, Jose M Miró, Albert Pahissa

Antiviral therapy 2005;10(5):605-14

Full Text

Abstract

Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.

Eugenia Negredo, Josep Ribalta, Raimon Ferré, Juliana Salazar, Celestino Rey-Joly, Guillem Sirera, Lluís Masana, Bonaventura Clotet

AIDS (London, England) 2004;18(5):819-21

Full Text

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

Mark Dybul, Elizabeth Nies-Kraske, Robin Dewar, Frank Maldarelli, Claire W Hallahan, Marybeth Daucher, Stephen C Piscitelli, Linda Ehler, Ann Weigand, Sarah Palmer, Julia A Metcalf, Richard T Davey, Diane M Rock Kress, April Powers, Ingrid Beck, Lisa Frenkel, Michael Baseler, John Coffin, Anthony S Fauci

The Journal of infectious diseases 2004;189(11):1974-82

Full Text

Abstract

The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy.

Michael P Dubé, Douglas W Kitch, Robert A Parker, Beverly L Alston-Smith, Kathleen Mulligan

Clinical chemistry and laboratory medicine 2005;43(9):947-52

Full Text

Abstract

L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine.

Sonia Moretti, Giuseppe Famularo, Sonia Marcellini, Antonio Boschini, Gino Santini, Vito Trinchieri, Luciano Lucci, Edoardo Alesse, Claudio De Simone

Antioxidants & redox signaling 2003;4(3):391-403

Full Text

Abstract

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).

Jean-Michel Molina, Valérie Journot, André Furco, Pierre Palmer, Nathalie De Castro, François Raffi, Philippe Morlat, Thierry May, Corinne Rancinan, Geneviève Chêne

Antiviral therapy 2007;12(3):417-22

Full Text

Abstract

Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

Jintanat Ananworanich, Angele Gayet-Ageron, Kiat Ruxrungtham, Ploenchan Chetchotisakd, Wisit Prasithsirikul, Sasisopin Kiertiburanakul, Warangkana Munsakul, Phitsonu Raksakulkarn, Somboon Tansuphasawadikul, Michelle LeBraz, Thidarat Jupimai, Sasiwimol Ubolyam, Malte Schutz, Bernard Hirschel

Antiviral therapy 2008;13(3):375-80

Full Text

Abstract

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

Margaret Johnson, Beatriz Grinsztejn, Claudia Rodriguez, Jeffrey Coco, Edwin DeJesus, Adriano Lazzarin, Kenneth Lichtenstein, Victoria Wirtz, Anna Rightmire, Linda Odeshoo, Colin McLaren

AIDS (London, England) 2006;20(5):711-8

Full Text

Abstract

Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.

Rupak Shivakoti, Nikhil Gupte, Wei-Teng Yang, Noluthando Mwelase, Cecilia Kanyama, Alice M Tang, Sandy Pillay, Wadzanai Samaneka, Cynthia Riviere, Sima Berendes, Javier R Lama, Sandra W Cardoso, Patcharaphan Sugandhavesa, Richard D Semba, Parul Christian, Thomas B Campbell, Amita Gupta

Nutrients 2015;6(11):5061-78

Free Full Text

Abstract

Seminal reservoirs during an HIV type 1 eradication trial.

Giuseppe Nunnari, Daniela Leto, Julie Sullivan, Yan Xu, Ketti E Mehlman, Joseph Kulkosky, Roger J Pomerantz

AIDS research and human retroviruses 2005;21(9):768-75

Full Text

Abstract

Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.

F D Goebel, G J Claas, B Jülg, Johannes R Bogner

European journal of medical research 2007;12(2):54-60

Full Text

Abstract

Results: 1 – 14 / 14

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Didanosine""[mesh_terms]

Unusual muscle disease in HIV infected patients.

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy.

L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine.

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).

Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.

Seminal reservoirs during an HIV type 1 eradication trial.

Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.

Results for
""Didanosine""[mesh_terms]